Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

Inclusion Criteria: * Considered appropriate candidate for allogeneic HCT following low dose (4Gy) TBI containing-conditioning and have one of the following diagnoses: A) BMF B)Hemoglobinopathies C)PID D) Autoimmune cytopenias E) Immune dysregulation F) HLH G) Other NMD treatable by HCT and NMD that is not clearly defined (a patient with a NMD for whom genetic testing has been done and a genetic mutation responsible for their NMD phenotype has not been identified) are eligible for the study following discussion with and approval by the protocol PI * Patients aged 6 months- 5 years old (inclusive) at the time of informed consent * Patient with suitable HCT donor (see inclusion criteria below) * Recipient informed consent/assent (13 years and older), and/or legal guardian permission must be obtained Exclusion Criteria: * Patient with aplastic anemia * Patients with severe combined immunodeficiency (SCID) * Fanconi anemia * Dyskeratosis congenita * Patient weight \> 100 kg * Patients who are positive for HIV-1, HIV-2 * Patients with current neoplastic disorders * Patients with uncontrolled infections for whom HCT is considered contraindicated by the consulting infectious disease physician. * Patients with organ dysfunction including A) Renal insufficiency B) Impaired cardiac function C)Impaired pulmonary function D) Liver dysfunction * Patients who are pregnant or breast-feeding * Patients on other experimental protocols for prevention of GVHD * Patients of childbearing age w…